Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Has documented chronic HCV GT1 infection (for Arm 4 participants may have GT4 or GT6 infection) with no evidence of non-typable or mixed genotype infection~* Has clinical evidence of hepatic cirrhosis with a score on the Child-Pugh scale from 7 to 9 and not anticipated to receive a liver transplant within the next 36 weeks (for Arm 1, Arm 3, and Arm 4)~* Has no evidence of cirrhosis (only for Arm 2 )~* Agrees to remain truly abstinent or use (or have their partner use) an acceptable method of birth control from at least 2 weeks prior to Day 1 and continue until at least 14 days after last dose of study drug, or longer if dictated by local regulations~Exclusion criteria:~* Is co-infected with hepatitis B virus or human immunodeficiency virus (HIV)~* Has previously received direct-acting antiviral therapy for HCV~* Has a history of malignancy \<=5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or under evaluation for other active or suspected malignancy~* Has cirrhosis and liver imaging results within 4 weeks prior to screening showing evidence of hepatocellular carcinoma (HCC), or is under evaluation for HCC~* Is currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another such study during the course of this study~* Has clinically-relevant drug or alcohol abuse within 12 months of screening~* Is pregnant or breast-feeding, or expecting to conceive or donate eggs or sperm from at least 2 weeks prior to Day 1 and continue throughout treatment and follow up, or longer if dictated by local regulations~* Has received organ transplants (including hematopoietic stem cell transplants) other than cornea and hair~* Has poor venous access~* Has a history of gastric surgery (e.g., stapling, bypass) or history of malabsorption disorders (e.g., celiac sprue disease)~* Requires, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* Has evidence or history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: CP-B GZR 50 mg + EBR 50 mg (Type: EXPERIMENTAL): CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
- Part A: NC GZR 100 mg + EBR 50 mg (Type: EXPERIMENTAL): NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
- Part B: CP-B GZR 100 mg + EBR 50 mg (Type: EXPERIMENTAL): CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
- Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg (Type: EXPERIMENTAL): CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete